DRCR.net Overview

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

 

Click here to view the presentation

Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF Therapy

Click here to view the presentation

Eye Council Presentation October 2018

Click here to view the presentation

 
Primary Outcome Presentations
 
1.     Protocol I - Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema Click here for presentation

2.     Protocol I - Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year Randomized Trial Results Click here for presentation

3.     Protocol I - 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for Diabetic Macular Edema Click here for presentation

4.     Protocol M - Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control Click here for presentation 

5.     Protocol N - Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Intravitreal Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy Click here for presentation

6.    Protocol T - A Comparative Effectiveness  Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Click here for presentation 
 
Secondary Outcome Presentations
  
1.     Protocol I - Rationale for the DRCR.net Treatment Protocol for Center-Involved DME Click here for presentation
 
2.     Protocol I - Green or Yellow Laser Treatment for Diabetic Macular Edema Click here for presentation
  
3.     Protocol I - Expanded 2-year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema Click here for presentation
 
4.     Protocol I - Worsening of Diabetic Retinopathy in a Randomized Clinical Trial Evaluating Ranibizumab and Triamcinolone: Exploratory Analysis Click here for presentation
 
5.     Protocol I - Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for Ocular Hypotensive Treatment Click here for presentation
 
6.     Protocol I - Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment or Diabetic Macular Edema Click here for presentation
  
7.     Protocol I - An Evaluation of Study Participant Masking of Intraocular Injections in a Randomized Clinical Trial Click here for presentation
 
8.     Protocol I - Persistent Macular Thickening After Ranibizumab Treatment or Diabetic Macular Edema with Vision Impairment: An Exploratory Analysis  Click here for presentation
 
 9.    General - The Importance of Using Povidone-Iodine and Elimination of Topical Antibiotics for Intravitreous Injections: Update from the DRCR.net Click here for presentation
 
10.   Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema in Eyes with Vitrectomy Prior to Anti-Vascular Endothelial Growth Factor Therapy Click here for presentation

  11.    Cost-Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema  sTreatment: Analysis from the Diabetic Retinopathy Clinical Research Network Comparative  sEffectiveness Trial Click here for presentation